Letter to the Editor

Chickenpox and Pneumonia Following Varicella Vaccine

To the Editor:

Vaccination, although highly effective for preventing disease, may be occasionally associated with adverse side effects.

A 24-year-old resident of a developmental center, who had been previously vaccinated against all childhood diseases, was serosusceptible to varicella. Per official guidelines,1 she was given 0.5 mL of varicella vaccine subcutaneously (OKA strain; Varivax, Merck, Whitehouse Station, NJ).

After 18 days, she had a fever (temperature, 38°C to 39°C) and a maculopapular rash on her trunk. On day 19, the papules changed to monolocular collapsing vesicles. On day 20, a similar rash appeared on her extremities and face. Successive crops of rash resulted in the presence of several stages of vesicle maturation. The total number of lesions was estimated to be 150 to 200. On day 21, she developed more skin lesions and a mild dehydration. A chest radiograph revealed a right basilar pulmonary collapse, with negative pressure ventilation being necessary.

The patient eventually recovered. The hospital costs, excluding physician fees, totaled $48,523 and were adjudicated and paid by Medicaid.

To the Editor:

Vaccination, although highly effective for preventing disease, may be occasionally associated with adverse side effects.

A 24-year-old resident of a developmental center, who had been previously vaccinated against all childhood diseases, was serosusceptible to varicella. Per official guidelines,1 she was given 0.5 mL of varicella vaccine subcutaneously (OKA strain; Varivax, Merck, Whitehouse Station, NJ).

After 18 days, she had a fever (temperature, 38°C to 39°C) and a maculopapular rash on her trunk. On day 19, the papules changed to monolocular collapsing vesicles. On day 20, a similar rash appeared on her extremities and face. Successive crops of rash resulted in the presence of several stages of vesicle maturation. The total number of lesions was estimated to be 150 to 200. On day 21, she developed more skin lesions and a mild dehydration. A chest radiograph revealed a right basilar pulmonary collapse, with negative pressure ventilation being necessary.

The patient eventually recovered. The hospital costs, excluding physician fees, totaled $48,523 and were adjudicated and paid by Medicaid.

The most likely cause of this illness was the vaccination because of its temporal consistency with the incubation period of varicella (14 to 21 days) and the lack of any contemporaneous case of wild varicella among staff or other residents. Although a mild rash (median, 5 lesions) may appear in 3% of individuals vaccinated against varicella, disseminated eruption is rare and pneumonia has occurred in only 0.0002% of these individuals.2 This case was reported to the Vaccine Adverse Event Reporting System. On further review of this case, it was determined that this patient had panhypopituitarism and had been receiving 22.5 mg/d of hydrocortisone.

Live attenuated viral vaccines such as Varivax are contraindicated for individuals receiving immunosuppressive doses of corticosteroids (≥100 mg/d of hydrocortisone or equivalent). However, corticosteroid administration in the form of naturally produced hydrocortisone in replacement doses (equivalent to the body’s natural daily synthesis, such as 22.5 mg/d)3 is not considered a contraindication for live vaccines.4

Serious complications of vaccination, requiring expensive medical care or hospitalization, may discourage vaccine acceptance by the public,5 particularly for vaccines such as varicella not covered by the National Childhood Vaccine Injury Act of 1986.6 Varicella is a highly contagious infection that, in the prevaccine era, caused nearly 4 million illnesses, 11,000 hospitalizations, and 100 deaths annually in the United States. Since vaccine licensure in 1995, there has been a steady decline in these numbers.7 In a recent outbreak among vaccinated children, vaccination had an 85% efficacy in preventing varicella of any severity, and a 98% efficacy in preventing moderate to severe illness.8 Such observations underscore the importance of vaccination for varicella control. To maintain high vaccination rates, it is therefore necessary to continue educational efforts that stress the high benefit-to-risk ratio of vaccination, the low incidence of adverse reactions, and our ability to successfully manage such reactions if they do occur. For example, during 25 years of vaccination experience with approximately 1,000 residents and 2,000 employees (75,000 person-years) at this facility, one of us (GL) has observed only 2 other noteworthy adverse reactions to vaccines, both of which fully resolved.9,10

REFERENCES


Ghan-Shyam Lohiya, MD, MS
Lilia Tan-Figueroa, MD
Sailaja Reddy, MD
Fairview Developmental Center
Costa Mesa, CA
Helping to prevent moments like this.

Safety Solutions...

BD BACTEC™

Blood Culture System

Safety Solution: A blood culture bottle with a safety neck that works with standard adapters.

We don't want this to happen to you. That is why we have taken the extra step to design a blood culture bottle with a safety neck that is compatible with standard and readily available adapters. If you are having problems drawing blood cultures safely, let us help.

BD Diagnostics
7 Loveton Circle
Sparks, MD 21152-0999
800.638.8663
www.bd.com/ds

BD, BD Logo and BACTEC are trademarks of Becton, Dickinson and Company. ©2004 BD.